MedTrace Logo

Doppler Evaluation in RA Patients After Adalimumab.

NCT01609205 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-04-25

No results posted yet for this study

Summary

The purpose is to study the relationship between RA disease activity based on Doppler quantification and the subsequent clinical response (EULAR response) to treatment with Adalimumab during 12 months. The purpose is also to compare the Doppler quantification with conventional clinical methods and semiquantitative Doppler assessment.

Conditions

Interventions

BIOLOGICAL

Adalimumab

Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Hamed Rezaei

    lead OTHER

Principal Investigators

  • Monica Rydén Aulin, Phd · Karolinska Institutet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609205 on ClinicalTrials.gov